HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.

AbstractOBJECTIVES:
To examine the efficacy and safety of multi-target therapy using tacrolimus (TAC), mycophenolate mofetil (MMF) and a steroid as initial treatment for active lupus nephritis (LN).
METHODS:
We conducted a retrospective analysis of the data of 16 consecutive patients who received the multi-target therapy for active Classes III-V LN at our department. We also compared the outcomes of the multi-target therapy with those of TAC therapy (TAC + steroid), a study of which we had conducted previously in 13 patients with active LN (TAC group).
RESULTS:
All the patients treated with multi-target therapy achieved complete remission (CR) (mean, 4.6 ± 3.8 months; range, 1-15 months). The clinical profiles of the patients of the multi-target group were similar to those of the TAC group at baseline, except for a significantly higher level of proteinuria (4.6 ± 2.8 vs. 2.5 ± 2.1 g/gCr, p = 0.033) in the former. The CR rate at 6 months was significantly higher in the multi-target group as compared with that in the TAC group (81% vs. 38%, p = 0.018). Two cases of serious adverse events were associated with cytomegalovirus infection in the multi-target group, namely gastric ulcer and pancytopenia, both of which were successfully treated by antiviral therapy.
CONCLUSIONS:
Multi-target therapy was effective as initial treatment for active LN, with CR achieved early and in a high percentage of patients. Although this therapy was generally well tolerated, it is important to bear in mind the associated risk of cytomegalovirus infection.
AuthorsHidekazu Ikeuchi, Keiju Hiromura, Satoshi Takahashi, Keiichiro Mishima, Noriyuki Sakurai, Toru Sakairi, Yoriaki Kaneko, Akito Maeshima, Takashi Kuroiwa, Yoshihisa Nojima
JournalModern rheumatology (Mod Rheumatol) Vol. 24 Issue 4 Pg. 618-25 (Jul 2014) ISSN: 1439-7609 [Electronic] England
PMID24252014 (Publication Type: Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Prednisolone
  • Mycophenolic Acid
  • Tacrolimus
Topics
  • Adult
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunosuppressive Agents (adverse effects, therapeutic use)
  • Lupus Nephritis (drug therapy)
  • Male
  • Middle Aged
  • Mycophenolic Acid (adverse effects, analogs & derivatives, therapeutic use)
  • Prednisolone (adverse effects, therapeutic use)
  • Remission Induction
  • Retrospective Studies
  • Tacrolimus (adverse effects, therapeutic use)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: